Tumor Markers and Thyroid Cells

Thyroid cancer can be detected and monitored through the use of tumor markers, which are substances produced by cancer cells. Different types of thyroid cells produce different tumor markers.

Parafollicular cells, also known as clear cells or C cells, produce calcitonin, which is a tumor marker for medullary thyroid carcinoma (MTC). Elevated levels of calcitonin in the blood can indicate the presence of MTC and can also be used to monitor for recurrence after treatment.

Follicular cells produce thyroglobulin, which is a tumor marker for papillary and follicular thyroid tumors. Monitoring thyroglobulin levels can help detect the presence of these types of thyroid cancer and monitor for recurrence.

Pericytes, colloid cells, and endothelial cells do not produce any tumor markers and therefore cannot be used for cancer detection or monitoring.

Tumour Markers: Types and Uses

Tumour markers are substances produced by cancer cells or normal cells in response to cancer. They can be used to diagnose cancer, monitor treatment response, and detect recurrence. Here are some common tumour markers and their uses:

Carcinoembryonic antigen (CEA): This glycoprotein is found in normal mucosal cells but increases in adenocarcinoma, particularly colorectal cancer. It is used to monitor disease, rather than as a diagnostic tool.

CA-19-9: This intracellular adhesion molecule is highly specific for pancreatic and biliary tract cancers but may also be elevated in other cancers. It has a role in predicting metastatic disease.

Alpha fetoprotein (AFP): This tumour marker is used for hepatocellular carcinoma and non-seminomatous germ cell tumours. It can be used to screen for hepatocellular carcinomas, especially in high-risk patients.

C-reactive protein (CRP): This marker indicates acute inflammation and is not specific to cancer.

CA-125: This glycoprotein is a marker for ovarian cancer but can also be elevated in other intra-abdominal cancers and non-malignant conditions. It is mainly used for monitoring after treatment and if ovarian cancer is suspected.

In conclusion, tumour markers have various uses in cancer diagnosis and management. However, they should always be interpreted in conjunction with other clinical and imaging findings.

Appropriate Procedures for a Hospice Patient

When a patient is admitted to hospice care, their medical treatment shifts towards end-of-life measures and comfort. In this context, certain procedures may not be appropriate or beneficial for the patient.

Paracentesis is a procedure that may be helpful for a hospice patient experiencing pain due to ascites. This condition is often caused by low albumin levels, which can be due to malabsorption or liver disease.

Colonoscopy and exploratory laparotomy are invasive procedures that require sedation and post-operative pain management. These procedures are unlikely to provide added benefit to a patient with a terminal diagnosis who is on comfort measures.

Flexible sigmoidoscopy is a simpler procedure that may be used to investigate for colon masses in patients with iron deficiency anemia.

Upper gastrointestinal endoscopy may be considered for symptom relief, but is not typically indicated for a hospice patient.

In summary, the appropriateness of a medical procedure for a hospice patient should be carefully considered in the context of their end-of-life care plan.

Appropriate Procedures for a Hospice Patient

Myth-busting: Tongue Cancer Risk Factors

Tongue cancer is a rare form of oral carcinoma, accounting for only 2% of overall cancers. While it can be associated with human papillomavirus (HPV), there are several misconceptions about its risk factors. Contrary to popular belief, smoking and alcohol are known risk factors, while coconut ingestion is not. Betel nut ingestion, on the other hand, is associated with an increased risk of tongue cancer. It is important to note that tongue cancer usually metastasises to the upper cervical and submandibular nodes, not the lower cervical nodes. However, early detection and treatment with a combination of surgery and chemoradiotherapy can often lead to a cure.

TNM Staging and Examples

TNM staging is a system used to describe the extent of cancer in a patient’s body. It takes into account the size of the tumor (T), whether it has spread to nearby lymph nodes (N), and whether it has metastasized to distant organs (M). The categories are further subdivided to provide more detailed information. Based on the TNM categories, cancers are grouped into stages, which help determine the most appropriate treatment options.

Examples of TNM staging include:

– T1, N1, M0: The tumor is ≤2 cm in size (T1), one local axillary node is positive (N1), and there are no distant metastases (M0).
– T0, Nx, M0: The tumor is ≤2 cm in size (T1), and there was one positive axillary lymph node (N1). Nx would mean that spread to local lymph nodes was not assessed.
– T1, N0, M1: There was one positive axillary lymph node (N1), and there are no distant metastases (M0).
– T2, N1, M0: The tumor is ≤2 cm in size (T1), and there was one positive axillary lymph node (N1).
– T1, N1, Mx: There are no distant metastases (M0).

Tumor Markers and Their Associated Cancers

Tumor markers are substances produced by cancer cells that can be detected in the blood. They can be useful in diagnosing and monitoring certain types of cancer. Here are some common tumor markers and the cancers they are associated with:

– CA 19-9: This marker is associated with cholangiocarcinoma, but can also be positive in pancreatic and colorectal cancer.
– CA 15-3: This marker is associated with breast cancer.
– AFP: This marker is associated with hepatocellular carcinoma (HCC) and teratomas.
– CEA: This marker is associated with colorectal cancer.
– CA 125: This marker is associated with ovarian, uterine, and breast cancer.

It is important to note that tumor markers are not always specific to one type of cancer and should be used in conjunction with other diagnostic tests.

Tumor Markers and Their Association with Specific Cancers

Tumor markers are substances produced by cancer cells that can be detected in the blood. These markers can be used to screen for and monitor certain types of cancer. Here are some examples of tumor markers and their association with specific cancers:

– Alphafetoprotein (AFP) and hepatocellular carcinoma: AFP is raised in 80% of patients with hepatocellular carcinoma. High-risk patients should be offered 6-monthly screening with a combination of hepatic ultrasound and AFP level.
– CA 15-3 and breast cancer: CA 15-3 is associated with breast cancer.
– CA 19-9 and pancreatic and biliary tract cancers: CA 19-9 is associated with pancreatic and biliary tract cancers.
– CA 125 and ovarian cancer: CA 125 is associated with ovarian cancer.
– Prostate-specific antigen (PSA) and prostatic cancer: PSA is associated with prostatic cancer and benign prostatic hypertrophy.
– Testicular cancer: Testicular cancer can be associated with AFP, human chorionic gonadotropin (hCG) and lactate dehydrogenase (LDH), depending on the tumor type.

It is important to note that tumor markers are not always specific to one type of cancer and can also be elevated in non-cancerous conditions. Therefore, tumor markers should always be interpreted in conjunction with other diagnostic tests and clinical findings.

Treatment Options for Small Cell Lung Cancer

Small cell lung cancer is a type of lung cancer that is often treated with a combination of chemotherapy and radiotherapy. According to NICE guidelines, concurrent chemoradiotherapy is the recommended first-line treatment for limited-stage disease. Radiotherapy alone is less effective than combination therapy.

Surgery is not routinely recommended for limited disease, but may be considered for patients with very early stage disease. Interferon-alpha is no longer recommended for small cell lung cancer.

For patients with extensive metastatic disease, palliative chemotherapy may be offered. However, this decision should be discussed with the patient. In the case of a patient without significant co-morbidities and no metastases, other treatment options may be considered.

Immunological Therapies for Breast Cancer: A Comparison of Trastuzumab, Infliximab, and Rituximab

Breast cancer is a prevalent disease among women, and HER-2 receptor positive breast cancers have a worse prognosis. Trastuzumab, a monoclonal antibody therapy, has improved the treatment and survival of HER-2 positive breast cancers. On the other hand, Infliximab, a monoclonal antibody against tumour necrosis factor alpha, is used to treat autoimmune diseases and has no role in breast carcinoma treatment. Rituximab, another immunological therapy, is primarily used in the management of rheumatoid disease. Tamoxifen, a hormonal therapy, is used in the treatment of breast cancer when the carcinoma is confirmed as oestrogen receptor positive (ER+). Doxorubicin, a chemotherapy agent, is used in the treatment of advanced breast cancer. Understanding the differences between these therapies is crucial in determining the best treatment plan for breast cancer patients.

Management of Neutropenic Sepsis in a Post-Chemotherapy Patient

When a patient presents with neutropenic sepsis post-chemotherapy, it is crucial to start a broad-spectrum antibiotic immediately, without waiting for blood results or investigations. Tazocin is the first-line antibiotic recommended by NICE, but local hospital guidelines should be consulted if there is a known penicillin allergy. The Sepsis 6 protocol should be initiated promptly, and antibiotics should be administered within an hour of presentation. Once the patient is stabilized, an urgent chest X-ray can be performed. While granulocyte-colony stimulating factor (G-CSF) administration may have a role in selected patients, it is not routinely used in neutropenic sepsis. Consultation with the haematology team is also recommended.